Tucatinib

Experienced CEO brings deep oncology drug development and corporate strategy experience to Corrixr's board as the company advances CXR101 toward the clinic NEWARK, Del.--(BUSINESS WIRE)--Corrixr Therapeutics, a pre-clinical genetic medicine company targeting lung, head & neck, and esophageal squamous cell carcinomas, today announced the appointment of Nancy Whiting, PharmD, as Chair of the Board of Directors, succeeding Janice E. Nevin, M.D., MPH. The transition follows Dr. Nevin’s announcement that she will retire from ChristianaCare effective September 1, 2026. Dr. Nevin will remain on Corrixr’s board, as will Jenn Schwartz, who will succeed her as President and CEO of ChristianaCare, continuing ChristianaCare’s role as Corrixr’s founding institutional investor and partner. Dr. Whiting has served as CEO of Recludix Pharma for the past 5 years and brings an extensive track record across all phases of drug development, including over 15-years at Seagen, where she made significant contributions in her roles of Executive Vice President of Corporate Strategy and Executive Vice President of Clinical Development. She steps into the Chair role at a pivotal moment as Corrixr advances CXR101 toward IND filing and first-in-human proof-of-mechanism trials. “Nancy brings to the board the extensive oncology development and commercial experience Corrixr needs as it moves toward the clinic,” said Janice E. Nevin, M.D., MPH, President & CEO of ChristianaCare. “It has been an honor to chair Corrixr’s board as ChristianaCare’s founding institutional investor and partner, and to help guide the company from its origins at the Gene Editing Institute to this point.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “I’m thrilled to take on the Chair role at such a pivotal moment for the company,” said Nancy Whiting, PharmD. “Having spent my career bringing transformative oncology medicines through development and into the hands of patients, I see that same potential with Corrixr. I’m grateful to Janice for her leadership in building this board and look forward to working with her, Hilary, and the rest of the Corrixr team.” “Nancy’s appointment as Board Chair, strengthens Corrixr’s leadership at a pivotal moment as we advance toward the clinic,” said Hilary M. Malone, Ph.D., Chief Executive Officer of Corrixr. “I am deeply grateful to Janice Nevin for her vision, leadership and unwavering support of Corrixr, and I look forward to working with Nancy and Jenn Schwartz to build on that foundation and drive the company forward.” Corrixr is developing CXR101 to eliminate NRF2, a transcription factor consistently hyperactive in squamous cell cancers, directly at its genetic source. Unlike small-molecule approaches that attempt to inhibit NRF2 protein activity, CXR101 acts upstream, disrupting the mechanism that sustains squamous cell tumor survival without the toxicity associated with systemic exposure. Delivered locally via ionizable lipid nanoparticles, the approach collapses tumor survival, proliferation, immune evasion, and metabolic reprogramming in a single intervention. About Nancy Whiting, PharmD Nancy Whiting, PharmD, is the Chief Executive Officer of Recludix Pharma and has an established track record across all phases of drug development. Dr. Whiting is a 15-year veteran of Seagen, where she most recently served as Executive Vice President of Corporate Strategy, holding broad responsibility for corporate strategy and planning, strategic alliances and partnerships, investor relations, corporate communications, and information technologies. She previously served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Dr. Whiting played a central role in the development and regulatory approval of ADCETRIS for lymphoma, PADCEV for bladder cancer, TUKYSA for breast cancer, TIVDAK for cervical cancer, and several other pipeline compounds. Prior to transitioning to the pharmaceutical industry, Dr. Whiting practiced as a Clinical Oncology Pharmacist at the Seattle Cancer Care Alliance. She completed her undergraduate training at the University of British Columbia and received her PharmD from the University of Washington and completed a residency in clinical pharmacy practice at Vancouver General Hospital. Dr. Whiting is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the European Society of Medical Oncology. She serves on the Board of Directors of Caribou Biosciences, Boundless Bio, and Biocom California. About Corrixr Therapeutics Corrixr Therapeutics is a genetic medicine company developing breakthrough treatments for squamous cell carcinomas of the lung, head & neck, and esophagus, among the deadliest and treatment-resistant cancers in the world. Corrixr's lead program, CXR101, targets NRF2, a transcription factor consistently hyperactive in squamous tumors that drives tumor survival. Using a proprietary CRISPR-based gene editing approach, CXR101 ablates NRF2 directly at the genetic source, with no reliance on small molecule binding, dismantling the biological mechanism these tumors cannot live without while aiming to reduce the burden patients experience with conventional therapies. Learn more at corrixr.com . Contacts Media: Jennifer Hanley 347-819-0402

胃癌发病率高，多数胃癌患者确诊时已处于不可切除的中晚期阶段，系统性治疗是其首选治疗方案。随着分子生物学和新型药物的不断发展，生物标记物指导下的胃癌精准治疗策略日渐成熟，HER2是胃癌重要靶点。 HER2是什么     人表皮生长因子受体2 (human epidermal growth factor receptor-2, HER2)基因，即cerbB-2基因，定位于染色体17q21，主要编码HER-2蛋白。HER-2蛋白是一种跨膜糖蛋白，在细胞增殖、分化、血管生成等过程中发挥重要作用。有研究报道，胃癌中HER2阳性率约为12%-18%。 作用机制     目前靶向HER2的药物主要有单克隆抗体、小分子络氨酸酶抑制剂（TKI）、抗体偶联药物（ADC）和新型抗体等。实现对HER2信号下游通路的阻断，从而抑制肿瘤生长和扩散。         HER2单克隆抗体是目前HER2过表达癌症靶向治疗的主要手段之一，代表药物就是曲妥珠单抗。这些抗体通过靶向HER2蛋白进行结合，可诱导抗体依赖性细胞介导的细胞毒作用（ADCC）和经典途径的补体活化，从而抑制肿瘤细胞的生长、分裂和扩散。2010年，ToGA研究显示相比于单纯化疗组，曲妥珠单抗联合化疗中位总生存期更长，里程碑式的ToGA研究，是全球第一个证明靶向治疗能延长晚期胃癌生存时间的大型III期临床试验，曲妥珠单抗也成为了第一个在胃癌上探索成功的分子靶向药物，宣告了胃癌靶向治疗时代的到来。     抗体药物偶联物（antibody-drug conjugate，ADC）是一类抗体、连接头和细胞毒性药物组成的靶向生物药剂，以单抗为载体将小分子细胞毒性药物为靶向方式高效地运输至目标肿瘤细胞内发挥抗肿瘤的作用。ADC药物毒性对健康组织的危害小，同时发挥抑癌作用。代表性药物有维迪西妥单抗，DS-8201等。维迪西妥单抗在我国已获批用至少接受过 2 个系统化疗的HER2过表达局部晚期或转移性胃癌。DS-8201已在国外获批用于HER2阳性晚期乳腺癌、HER2低表达晚期乳腺癌，HER2阳性胃癌、HER2突变的非小细胞肺癌。以及最近在FDA批用于既往接受过系统治疗的转移性HER2阳性实体瘤患者。     酪氨酸激酶抑制剂高度选择性地抑制HER2蛋白酪氨酸激酶活性，持续抑制HER下游信号传导通路，最终促进细胞凋亡，抑制肿瘤细胞生长和增殖，发挥抗肿瘤活性。这类药物包括图卡替尼、拉帕替尼等，已经在临床上取得了一定的疗效。     当然目前还有新型抗体，例如HER2双特异性抗体，双特异性抗体可以同时靶向两个不同抗原，或者靶向同一抗原上的两个不同表位。双特异性抗体还可以通过一个结合位点靶向抗原，而另一个位点可以作为免疫靶点，从而引发协同效应，代表药物有ZW25，KN026等。     天津医科大学肿瘤医院消化肿瘤内科围绕着HER2靶点承担了国内外多项相关临床试验，为HER2阳性晚期胃肠癌患者的治疗提供更多更好的选择。